These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 29613856)
21. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Yang F; Shi P; Xi X; Yi S; Li H; Sun Q; Sun M Med Oncol; 2006; 23(2):191-204. PubMed ID: 16720919 [TBL] [Abstract][Full Text] [Related]
22. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070 [TBL] [Abstract][Full Text] [Related]
23. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1. Chen J; Cui JD; Guo XT; Cao X; Li Q Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886 [TBL] [Abstract][Full Text] [Related]
24. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
25. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
26. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157 [TBL] [Abstract][Full Text] [Related]
27. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458 [TBL] [Abstract][Full Text] [Related]
32. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition. Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374 [TBL] [Abstract][Full Text] [Related]
33. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Li F; Zhu T; Cao B; Wang J; Liang L Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888 [TBL] [Abstract][Full Text] [Related]
34. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Phuchareon J; McCormick F; Eisele DW; Tetsu O Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526 [TBL] [Abstract][Full Text] [Related]
35. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Juchum M; Günther M; Laufer SA Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435 [TBL] [Abstract][Full Text] [Related]
36. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
37. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103 [TBL] [Abstract][Full Text] [Related]
38. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib. Porcelli L; Giovannetti E; Assaraf YG; Jansen G; Scheffer GL; Kathman I; Azzariti A; Paradiso A; Peters GJ Curr Drug Targets; 2014; 15(14):1322-30. PubMed ID: 25479544 [TBL] [Abstract][Full Text] [Related]
39. miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1. Gan CZ; Li G; Luo QS; Li HM IUBMB Life; 2017 Nov; 69(11):841-849. PubMed ID: 28940895 [TBL] [Abstract][Full Text] [Related]
40. MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. Chen Y; Zhou X; Qiao J; Bao A Cell Physiol Biochem; 2017; 41(4):1370-1382. PubMed ID: 28427045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]